epzm-10q_20200331.htm
false 2020 Q1 0001571498 --12-31 Large Accelerated Filer true P7Y4M P12Y2M12D P8Y2M23D P6Y7M13D 0001571498 2020-01-01 2020-03-31 xbrli:shares 0001571498 2020-04-30 iso4217:USD 0001571498 2020-03-31 0001571498 2019-12-31 iso4217:USD xbrli:shares xbrli:pure 0001571498 us-gaap:ProductMember 2020-01-01 2020-03-31 0001571498 epzm:CollaborationRevenueMember 2020-01-01 2020-03-31 0001571498 epzm:CollaborationRevenueMember 2019-01-01 2019-03-31 0001571498 2019-01-01 2019-03-31 0001571498 2018-12-31 0001571498 2019-03-31 0001571498 us-gaap:CommonStockMember 2018-12-31 0001571498 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001571498 us-gaap:RetainedEarningsMember 2018-12-31 0001571498 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001571498 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001571498 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001571498 us-gaap:PreferredStockMember 2019-01-01 2019-03-31 0001571498 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001571498 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001571498 us-gaap:CommonStockMember 2019-03-31 0001571498 us-gaap:PreferredStockMember 2019-03-31 0001571498 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001571498 us-gaap:RetainedEarningsMember 2019-03-31 0001571498 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001571498 us-gaap:CommonStockMember 2019-12-31 0001571498 us-gaap:PreferredStockMember 2019-12-31 0001571498 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001571498 us-gaap:RetainedEarningsMember 2019-12-31 0001571498 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001571498 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001571498 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001571498 us-gaap:CommonStockMember epzm:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001571498 us-gaap:PreferredStockMember epzm:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001571498 us-gaap:AdditionalPaidInCapitalMember epzm:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001571498 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001571498 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001571498 us-gaap:CommonStockMember 2020-03-31 0001571498 us-gaap:PreferredStockMember 2020-03-31 0001571498 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001571498 us-gaap:RetainedEarningsMember 2020-03-31 0001571498 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001571498 epzm:TAZVERIKMember 2020-01-01 2020-03-31 0001571498 epzm:RoyaltyPharmaAndPharmakonAdvisorsMember 2020-01-01 2020-03-31 0001571498 epzm:EisaiMember 2020-01-01 2020-03-31 0001571498 epzm:RoyaltyPharmaMember 2020-01-01 2020-03-31 0001571498 epzm:BioPharmaCreditInvestmentsVMasterLPAndBioPharmaCreditPLCMember 2020-01-01 2020-03-31 0001571498 epzm:BioPharmaCreditInvestmentsVMasterLPAndBioPharmaCreditPLCMember 2020-03-31 0001571498 us-gaap:IPOMember 2020-01-01 2020-03-31 0001571498 epzm:TAZVERIKMember epzm:ChargebacksDiscountsAndFeesMember 2020-01-01 2020-03-31 0001571498 epzm:TAZVERIKMember epzm:GovernmentAndOtherRebatesMember 2020-01-01 2020-03-31 0001571498 epzm:TAZVERIKMember epzm:ReturnsMember 2020-01-01 2020-03-31 0001571498 epzm:TAZVERIKMember epzm:ChargebacksDiscountsAndFeesMember 2020-03-31 0001571498 epzm:TAZVERIKMember epzm:GovernmentAndOtherRebatesMember 2020-03-31 0001571498 epzm:TAZVERIKMember epzm:ReturnsMember 2020-03-31 0001571498 epzm:TAZVERIKMember 2020-03-31 0001571498 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember epzm:CustomerOneMember 2020-01-01 2020-03-31 0001571498 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember epzm:CustomerTwoMember 2020-01-01 2020-03-31 0001571498 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember epzm:CustomerThreeMember 2020-01-01 2020-03-31 0001571498 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember epzm:CustomerOneMember 2020-01-01 2020-03-31 0001571498 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember epzm:CustomerTwoMember 2020-01-01 2020-03-31 0001571498 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember epzm:CustomerThreeMember 2020-01-01 2020-03-31 epzm:Customer 0001571498 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001571498 us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2020-01-01 2020-03-31 0001571498 epzm:TAZVERIKMember 2019-01-01 2019-03-31 0001571498 us-gaap:LetterOfCreditMember epzm:TechnologySquareMember 2020-03-31 0001571498 us-gaap:LetterOfCreditMember epzm:HampshireStreetMember 2020-03-31 0001571498 us-gaap:CommercialPaperMember 2020-03-31 0001571498 us-gaap:CorporateNoteSecuritiesMember 2020-03-31 0001571498 us-gaap:USTreasuryAndGovernmentMember 2020-03-31 0001571498 us-gaap:CommercialPaperMember 2019-12-31 0001571498 us-gaap:CorporateNoteSecuritiesMember 2019-12-31 0001571498 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 epzm:Security 0001571498 us-gaap:CorporateNoteSecuritiesMember 2020-01-01 2020-03-31 0001571498 us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2020-03-31 0001571498 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:CorporateNoteSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 us-gaap:FairValueInputsLevel2Member us-gaap:USTreasuryAndGovernmentMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001571498 epzm:InitialTermMember 2020-01-01 2020-03-31 0001571498 epzm:ExtendedTermMember 2020-01-01 2020-03-31 0001571498 epzm:CambridgeMember epzm:BMRHampshireLLCMember 2019-08-16 2019-08-16 0001571498 epzm:CambridgeMember epzm:BMRHampshireLLCMember 2019-08-16 epzm:OptionTarget 0001571498 epzm:GskMember 2011-01-01 2011-01-01 0001571498 epzm:GskMember epzm:CollaborationRevenueMember 2011-01-01 2013-12-31 0001571498 epzm:GskMember 2020-03-31 0001571498 epzm:GskMember 2020-01-01 2020-03-31 0001571498 epzm:GskMember 2011-01-01 2019-12-31 0001571498 epzm:EisaiMember 2015-03-01 2015-03-31 0001571498 epzm:EisaiMember 2020-03-31 0001571498 epzm:EisaiMember epzm:FirstSubmissionOfNewDrugApplicationOrMarketingAuthorizationApplicationMember 2020-03-31 0001571498 epzm:EisaiMember 2019-01-01 2019-06-30 0001571498 epzm:EisaiMember epzm:SecondSubmissionOfNewDrugApplicationOrMarketingAuthorizationApplicationMember 2019-06-30 0001571498 epzm:EisaiMember epzm:SecondSubmissionOfNewDrugApplicationOrMarketingAuthorizationApplicationMember 2019-12-31 0001571498 epzm:EisaiMember 2019-06-30 0001571498 epzm:EisaiMember epzm:SecondSubmissionOfNewDrugApplicationOrMarketingAuthorizationApplicationMember 2020-01-31 0001571498 epzm:EisaiMember 2019-01-01 2019-03-31 0001571498 epzm:EisaiMember 2019-12-31 0001571498 us-gaap:CollaborativeArrangementMember epzm:RocheMember 2018-03-31 0001571498 us-gaap:CollaborativeArrangementMember epzm:RocheMember 2020-03-31 0001571498 epzm:RocheMember 2019-07-31 0001571498 epzm:SignedAmendmentMember epzm:RocheMember 2019-07-31 0001571498 epzm:FourthAmendmentMember epzm:RocheMember 2019-07-31 0001571498 epzm:RocheMember us-gaap:SubsequentEventMember 2020-06-30 0001571498 epzm:RocheMember 2020-01-01 2020-03-31 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2018-11-01 2018-11-30 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2018-11-30 epzm:Installment 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2020-03-31 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2020-01-01 2020-03-31 0001571498 srt:MaximumMember epzm:BoehringerIngelheimInternationalGmbHMember 2018-11-30 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2019-01-01 2019-09-30 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2019-09-30 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2019-12-31 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2019-01-01 2019-03-31 0001571498 epzm:BoehringerIngelheimInternationalGmbHMember 2019-03-31 0001571498 epzm:CelgeneMember 2012-04-01 2019-09-30 0001571498 epzm:CelgeneMember 2019-09-30 0001571498 epzm:LoanAgreementMember 2019-11-04 epzm:Tranche 0001571498 epzm:TrancheANotePayableMember epzm:LoanAgreementMember 2019-11-04 0001571498 epzm:TrancheBNotePayableMember epzm:LoanAgreementMember 2019-11-04 0001571498 epzm:TrancheCNotePayableMember epzm:LoanAgreementMember 2019-11-04 0001571498 epzm:TrancheANotePayableMember epzm:LoanAgreementMember 2020-03-31 0001571498 epzm:TrancheBNotePayableMember epzm:LoanAgreementMember 2020-03-31 0001571498 epzm:LoanAgreementMember srt:MaximumMember 2020-03-31 0001571498 epzm:LoanAgreementMember 2020-01-01 2020-03-31 0001571498 epzm:RPIPurchaseAgreementMember 2019-11-04 0001571498 epzm:RPIPurchaseAgreementMember srt:MaximumMember 2019-11-04 2019-11-04 0001571498 epzm:RPIPurchaseAgreementMember 2019-11-04 2019-11-04 0001571498 epzm:RPIPurchaseAgreementMember epzm:AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember 2019-11-04 2019-11-04 0001571498 epzm:RPIPurchaseAgreementMember 2020-02-01 2020-02-29 0001571498 epzm:RPIPurchaseAgreementMember epzm:LoanAgreementMember 2020-01-01 2020-03-31 0001571498 epzm:RPIPurchaseAgreementMember epzm:LoanAgreementMember 2020-03-31 0001571498 epzm:RPIPurchaseAgreementMember epzm:TrancheANotePayableMember epzm:LoanAgreementMember 2020-03-31 0001571498 epzm:RPIPurchaseAgreementMember 2020-01-01 2020-03-31 0001571498 us-gaap:RoyaltyArrangementMember 2020-01-01 2020-03-31 0001571498 us-gaap:RoyaltyArrangementMember 2020-03-31 0001571498 epzm:TazemetostatMember us-gaap:RoyaltyArrangementMember 2020-01-01 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember 2019-12-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheBNotePayableMember 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember 2019-01-01 2019-12-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheBNotePayableMember 2020-01-01 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember 2020-01-01 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember epzm:NovemberEighteenTwoThousandTwentyTwoMember 2020-01-01 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember epzm:NovemberEighteenTwoThousandTwentyTwoToNovemberTwoThousandTwentyThreeMember 2020-01-01 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember epzm:NovemberEighteenTwoThousandTwentyThreeToNovemberEighteenTwoThousandTwentyFourMember 2020-01-01 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheANotePayableMember srt:MaximumMember 2020-03-31 0001571498 epzm:LoanAgreementsMember epzm:TrancheTermLoanMember epzm:BioPharmaCreditInvestmentsVMasterLPMember 2020-01-01 2020-03-31 0001571498 epzm:RPIPurchaseAgreementMember 2019-11-30 0001571498 us-gaap:CommonStockMember 2020-02-01 2020-02-29 0001571498 epzm:SeriesAConvertiblePreferredStockMember 2019-03-06 0001571498 epzm:SeriesAConvertiblePreferredStockMember 2019-03-06 2019-03-06 0001571498 epzm:SeriesAConvertiblePreferredStockMember 2020-03-31 0001571498 epzm:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001571498 us-gaap:PreferredStockMember 2020-02-01 2020-02-29 0001571498 us-gaap:CommonStockMember 2020-02-01 2020-02-29 0001571498 epzm:RPIPurchaseAgreementMember srt:MaximumMember 2019-11-01 2019-11-30 0001571498 epzm:RPIPurchaseAgreementMember 2019-11-01 2019-11-30 0001571498 epzm:RPIPurchaseAgreementMember us-gaap:AdditionalPaidInCapitalMember 2019-11-01 2019-11-30 0001571498 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001571498 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-03-31 0001571498 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001571498 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-03-31 0001571498 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001571498 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001571498 epzm:ServiceBasedRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001571498 epzm:ServiceBasedRestrictedStockUnitsMember 2019-12-31 0001571498 epzm:ServiceBasedRestrictedStockUnitsMember 2020-03-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember srt:ExecutiveOfficerMember 2020-01-01 2020-03-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2019-01-01 2019-12-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2019-01-01 2019-12-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2019-01-01 2019-12-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember epzm:ShareBasedCompensationAwardTrancheFourMember 2019-01-01 2019-12-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember 2019-12-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001571498 epzm:PerformanceBasedRestrictedStockUnitsMember 2020-03-31 0001571498 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001571498 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001571498 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-03-31 0001571498 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001571498 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-03-31 0001571498 epzm:EmployeeStockPurchasePlanMember 2020-01-01 2020-03-31 0001571498 epzm:EmployeeStockPurchasePlanMember 2019-01-01 2019-03-31 0001571498 us-gaap:ConvertiblePreferredStockMember 2020-01-01 2020-03-31 0001571498 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001571498 us-gaap:WarrantMember 2020-01-01 2020-03-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2020

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                      to                     

Commission File Number: 001-35945

 

EPIZYME, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

26-1349956

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

400 Technology Square, Cambridge, Massachusetts

02139

(Address of principal executive offices)

(Zip code)

617-229-5872

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock, $0.0001 par value

EPZM

Nasdaq Global Select Market

The number of shares outstanding of the registrant’s common stock as of April 30, 2020: 101,061,195 shares. 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

 

Non-accelerated filer

 

  

 

Smaller reporting company

 

 

 

 

 

 

 

 

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act). 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

 

 

 


 

PART I — FINANCIAL INFORMATION

 

 

 

Item 1. Financial Statements. — Unaudited

4

 

 

Condensed Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019

4

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2020 and 2019

5

 

 

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019

6

 

 

Condensed Consolidated Statements of Stockholders Equity

7

 

 

Notes to Condensed Consolidated Financial Statements

8

 

 

Item  2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

27

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

37

 

 

Item 4. Controls and Procedures

37

 

 

PART II — OTHER INFORMATION

 

 

 

Item 1A. Risk Factors

39

 

 

Item 6. Exhibits

72

 

 

Signatures

73

 

Epizyme® is a registered trademark of Epizyme, Inc. and Epizyme, Inc. has submitted trademark applications for TAZVERIK™ in the United States and/or other countries. All other trademarks, service marks or other tradenames appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

 

 

 


 

Forward-looking Information

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. These statements may be identified by such forward-looking terminology as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar statements or variations of such terms. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

 

our plans to develop and commercialize novel epigenetic therapies for patients with cancer and other serious diseases;

 

the commercial launch of TAZVERIK;

 

our ongoing and planned clinical trials, including the timing of initiation and enrollment in the trials, the timing of availability of data from the trials and the anticipated results of the trials;

 

the timing of and our ability to apply for, obtain and maintain regulatory approvals for our product candidates;

 

our ability to achieve anticipated milestones under our collaborations;

 

the rate and degree of market acceptance and clinical utility of our products;

 

our commercialization, marketing and manufacturing capabilities and strategy;

 

our intellectual property position; and

 

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

All of our forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the Securities and Exchange Commission, or the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q which modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

Our management’s discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim periods and with Regulation S-X promulgated under the Securities Exchange Act of 1934, as amended, or the Exchange Act. This discussion and analysis should be read in conjunction with these unaudited condensed consolidated financial statements and the notes thereto as well as in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, or our Annual Report. The three months ended March 31, 2020 and 2019 are referred to as the first quarter of 2020 and 2019, respectively. Unless the context indicates otherwise, all references herein to our company include our wholly owned subsidiary.

 

3


 

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements

EPIZYME, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(Amounts in thousands, except per share data)

 

 

 

March 31,

2020

 

 

December 31,

2019

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

179,262

 

 

$

139,482

 

Marketable securities

 

 

197,199

 

 

 

241,605

 

Accounts receivable, net

 

 

1,649

 

 

 

2,567

 

Inventory

 

 

1,703

 

 

 

 

Prepaid expenses and other current assets

 

 

22,627

 

 

 

15,523

 

Total current assets

 

 

402,440

 

 

 

399,177

 

Property and equipment, net

 

 

2,071

 

 

 

2,219

 

Operating lease assets

 

 

20,473

 

 

 

21,206

 

Intangible assets, net

 

 

24,702

 

 

 

 

Restricted cash and other assets

 

 

1,951

 

 

 

1,987

 

Total assets

 

$

451,637

 

 

$

424,589

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,928

 

 

$

8,782

 

Accrued expenses

 

 

18,060

 

 

 

22,549

 

Current portion of operating lease obligation

 

 

3,179

 

 

 

3,039

 

Other current liabilities

 

 

16

 

 

 

16

 

Total current liabilities

 

 

27,183

 

 

 

34,386

 

Operating lease obligation, net of current portion

 

 

18,825

 

 

 

19,120

 

Deferred revenue, net of current portion

 

 

3,806

 

 

 

3,806

 

Long-term debt, net of debt discount

 

 

48,381

 

 

 

23,309

 

Other long-term liabilities

 

 

38

 

 

 

38

 

Liability related to sale of future royalties

 

 

13,087

 

 

 

12,793

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value; 5,000 shares authorized; 338 shares and

350 shares issued and outstanding, respectively (equivalent to 3,378 shares and 3,500 shares of common stock, respectively, upon conversion at a 10:1 ratio)

 

 

36,127

 

 

 

37,432

 

Common stock, $0.0001 par value; 125,000 shares authorized; 101,047

   shares and 97,783 shares issued and outstanding, respectively

 

 

10

 

 

 

10

 

Additional paid-in capital

 

 

1,112,211

 

 

 

1,050,695

 

Accumulated other comprehensive (loss) income

 

 

(75

)

 

 

19

 

Accumulated deficit

 

 

(807,956

)

 

 

(757,019

)

Total stockholders’ equity

 

 

340,317

 

 

 

331,137

 

Total liabilities and stockholders’ equity

 

$

451,637

 

 

$

424,589

 

 

See notes to condensed consolidated financial statements.

4


 

EPIZYME, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(Amounts in thousands, except per share data)

 

 

 

Three Months Ended

March 31,

 

 

 

2020

 

 

2019

 

Revenue:

 

 

 

 

 

 

 

 

Product revenue, net

 

$

1,284

 

 

$

 

Collaboration revenue

 

 

70

 

 

 

7,891

 

Total revenue

 

$

1,354

 

 

$

7,891

 

Operating expenses:

 

 

 

 

 

 

 

 

Cost of product revenue

 

 

614

 

 

 

 

Research and development

 

 

25,163

 

 

 

26,896

 

Selling, general and administrative

 

 

26,927

 

 

 

11,986

 

Total operating expenses

 

 

52,704

 

 

 

38,882

 

Operating loss

 

 

(51,350

)

 

 

(30,991

)

Other income, net:

 

 

 

 

 

 

 

 

Interest income, net

 

 

756

 

 

 

1,658

 

Other (expense), net

 

 

(48

)

 

 

(6

)

Non-cash interest expense related to sale of future royalties

 

 

(295

)

 

 

 

Other income, net

 

 

413

 

 

 

1,652

 

Net loss

 

$

(50,937

)

 

$

(29,339

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale securities

 

 

(94

)

 

 

86

 

Comprehensive loss

 

$

(51,031

)

 

$

(29,253

)

Reconciliation of net loss to net loss attributable to common stockholders:

 

 

 

 

 

 

 

 

Net loss

 

$

(50,937

)

 

$

(29,339

)

Accretion of convertible preferred stock

 

 

 

 

 

(2,940

)

Net loss attributable to common stockholders

 

$

(50,937

)

 

$

(32,279

)

Net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic

 

$

(0.51

)

 

$

(0.39

)

Diluted

 

$

(0.51

)

 

$

(0.39

)

Weighted-average common shares outstanding used in net loss per share attributable to common stockholders:

 

 

 

 

 

 

 

 

Basic

 

 

99,616

 

 

 

82,424

 

Diluted

 

 

99,616

 

 

 

82,424

 

 

See notes to condensed consolidated financial statements.

5


 

EPIZYME, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(Amounts in thousands)

 

 

 

Three Months Ended

March 31,

 

 

 

2020

 

 

2019

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(50,937

)

 

$

(29,339

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

512

 

 

 

207

 

Stock-based compensation

 

 

6,510

 

 

 

3,211

 

Amortization of discount on investments

 

 

(270

)

 

 

(690

)

Amortization of debt discount

 

 

83

 

 

 

 

Loss on disposal of property and equipment

 

 

19

 

 

 

 

Non-cash interest expense associated with the sale of future royalties

 

 

295

 

 

 

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

918

 

 

 

7,090

 

Inventory

 

 

(1,703

)

 

 

 

Prepaid expenses and other current assets

 

 

(7,104

)

 

 

(3,051

)

Accounts payable

 

 

(2,716

)

 

 

3,174

 

Accrued expenses

 

 

(4,489

)

 

 

(4,274

)

Deferred revenue

 

 

 

 

 

(7,891

)

Operating lease assets

 

 

733

 

 

 

943

 

Operating lease liabilities

 

 

(155

)

 

 

(963

)

Other assets

 

 

36

 

 

 

21

 

Net cash used in operating activities

 

 

(58,268

)

 

 

(31,562

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of available-for-sale securities

 

 

(13,999

)

 

 

(173,151

)

Maturities of available-for-sale securities

 

 

58,578

 

 

 

100,720

 

Purchase of intangible asset

 

 

(25,000

)

 

 

 

Purchases of property and equipment

 

 

(63

)

 

 

(21

)

Net cash provided by (used in) investing activities

 

 

19,516

 

 

 

(72,452

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from issuance of common stock, net of commissions

 

 

 

 

 

122,992

 

Proceeds from issuance of preferred stock, net of commissions

 

 

 

 

 

37,432

 

Payment of offering costs

 

 

(79

)

 

 

(22

)

Proceeds from the issuance of debt

 

 

25,000

 

 

 

 

Payment of debt issuance costs

 

 

(90

)

 

 

 

Proceeds from the issuance of common stock in connection with the exercise of the put option, net of financing costs

 

 

49,915

 

 

 

 

Proceeds from stock options exercised

 

 

3,140

 

 

 

886

 

Issuance of shares under employee stock purchase plan

 

 

646

 

 

 

360

 

Net cash provided by financing activities

 

 

78,532

 

 

 

161,648

 

Net increase in cash, cash equivalents and restricted cash

 

 

39,780

 

 

 

57,634

 

Cash, cash equivalents and restricted cash, beginning of period

 

 

140,991

 

 

 

87,133

 

Cash, cash equivalents and restricted cash, end of period

 

$

180,771

 

 

$

144,767

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Unpaid offering costs

 

$

 

 

$

262

 

Interest paid

 

$

914

 

 

$

 

Property and equipment included in accounts payable or accruals

 

$

22

 

 

$

 

 

See notes to condensed consolidated financial statements

 

6


 

EPIZYME, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDER’S EQUITY

(Amounts in thousands, except share amounts)

 

 

 

Common Stock

 

 

Preferred Stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Accumulated

Other

Comprehensive

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at December 31, 2018

 

 

79,175,380

 

 

$

8

 

 

 

 

 

$

 

 

$

819,779

 

 

$

(586,724

)

 

$

(54

)

 

$

233,009

 

Issuance of common stock (net of commissions and offering costs of $284)

 

 

11,500,000

 

 

 

1

 

 

 

 

 

 

 

 

 

122,707

 

 

 

 

 

 

 

 

 

122,708

 

Issuance of series A convertible preferred stock, net of commissions and

   beneficial conversion charge

 

 

 

 

 

 

 

 

350,000

 

 

 

34,492

 

 

 

2,940

 

 

 

 

 

 

 

 

 

37,432

 

Accretion of series A convertible preferred stock

 

 

 

 

 

 

 

 

 

 

 

2,940

 

 

 

(2,940

)

 

 

 

 

 

 

 

 

 

Exercise of stock options and vesting of restricted stock units

 

 

89,726

 

 

 

 

 

 

 

 

 

 

 

 

886

 

 

 

 

 

 

 

 

 

886

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,211

 

 

 

 

 

 

 

 

 

3,211

 

Issuance of shares under employee stock purchase plan

 

 

37,972

 

 

 

 

 

 

 

 

 

 

 

360

 

 

 

 

 

 

 

 

 

360

 

Unrealized gain on available for sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

86

 

 

 

86

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(29,339

)

 

 

 

 

 

(29,339

)

Balance at March 31, 2019

 

 

90,803,078

 

 

$

9

 

 

 

350,000

 

 

$

37,432

 

 

$

946,943

 

 

$

(616,063

)

 

$

32

 

 

$

368,353

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2019

 

 

97,783,476

 

 

$

10

 

 

 

350,000

 

 

 

37,432

 

 

$

1,050,695

 

 

$

(757,019

)

 

$

19

 

 

$

331,137

 

Issuance of common stock in connection with the exercise of the put option (net of financing costs of $85)

 

 

2,500,000

 

 

 

 

 

 

 

 

 

 

 

 

49,915

 

 

 

 

 

 

 

 

 

49,915

 

Issuance of common stock in connection with the conversion of series A convertible preferred stock

 

 

122,000

 

 

 

 

 

 

(12,200

)

 

 

(1,305

)

 

 

1,305

 

 

 

 

 

 

 

 

 

 

Exercise of stock options and vesting of restricted stock units

 

 

579,919

 

 

 

 

 

 

 

 

 

 

 

 

3,140

 

 

 

 

 

 

 

 

 

3,140

 

Stock-based compensation

 

 

 

 

 

 

 

 

 

 

 

 

 

 

6,475

 

 

 

 

 

 

 

 

 

6,475

 

Issuance of shares under employee stock purchase plan

 

 

60,576

 

 

 

 

 

 

 

 

 

 

 

646

 

 

 

 

 

 

 

 

 

646

 

Issuance of shares of common stock in lieu of board fees

 

 

1,404

 

 

 

 

 

 

 

 

 

 

 

 

35

 

 

 

 

 

 

 

 

 

35

 

Unrealized loss on available for sale securities

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(94

)

 

 

(94

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(50,937

)

 

 

 

 

 

(50,937

)

Balance at March 31, 2020

 

 

101,047,375

 

 

$

10

 

 

 

337,800

 

 

$

36,127

 

 

$

1,112,211

 

 

$

(807,956

)

 

$

(75

)

 

$

340,317

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

See notes to condensed consolidated financial statements.

 

7


 

EPIZYME, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. The Company

Epizyme, Inc. (collectively referred to with its wholly owned, controlled subsidiary, Epizyme Securities Corporation, as “Epizyme” or the “Company”) is a biopharmaceutical company that is committed to rewriting treatment for people with cancer and other serious diseases through the discovery, development, and commercialization of novel epigenetic medicines. By focusing on the genetic drivers of disease, the Company’s science seeks to match targeted medicines with the patients who need them.

Through March 31, 2020, the Company has raised an aggregate of $1,356.9 million to fund its operations. This includes $243.3 million of non-equity funding through its collaboration agreements, $198.1 million of funding received through agreements with RPI Finance Trust (“Royalty Pharma”) and BioPharma Credit Investments V (Master) LP and BioPharma Credit PLC  (the “Lenders”) consisting of $100.0 million in consideration received from the sale of shares of the Company’s common stock, a warrant to purchase shares of the Company’s common stock and rights to receive royalties from Eisai with respect to net sales by Eisai of tazemetostat products in Japan, $50.0 million from the sale of shares of the Company’s common stock pursuant to the Company’s exercise of its put option to sell shares of its common stock to Royalty Pharma, $50.0 million of borrowings under the Company’s loan facility with the Lenders less debt issuance costs of $1.7 million, $839.5 million from the sale of common stock and series A convertible preferred stock in the Company’s public offerings and $76.0 million was from the sale of redeemable convertible preferred stock in private financings prior to the Company’s initial public offering in May 2013. As of March 31, 2020, the Company had $376.5 million in cash, cash equivalents and marketable securities.

The Company’s lead product candidate tazemetostat is approved in the United States as TAZVERIK for the treatment of epithelioid sarcoma.  Commercial sales of TAZVERIK for the treatment of epithelioid sarcoma commenced in the first quarter of 2020. The Company commenced active operations in early 2008. Since its inception, the Company has generated an accumulated deficit of $808.0 million through March 31, 2020 and will require substantial additional capital to fund its research, development, and commercialization efforts. The Company is subject to risks common to companies in the biotechnology industry, including, but not limited to, risks of failure of commercialization, clinical trials and preclinical studies, the need to obtain additional financing to fund the future development and commercialization of tazemetostat and the rest of its pipeline, the need to obtain marketing approval for its product candidates, the need to successfully commercialize and gain market acceptance of its product candidates, dependence on key personnel, protection of proprietary technology, compliance with government regulations, development by competitors of technological innovations and ability to transition from clinical-stage manufacturing to commercial-stage production of products.

2. Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, or the Annual Report.

The unaudited condensed consolidated financial statements include the accounts of Epizyme, Inc. and its wholly owned, controlled subsidiary, Epizyme Securities Corporation. All intercompany transactions and balances of subsidiaries have been eliminated in consolidation. In the opinion of management, the information furnished reflects all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the condensed consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended March 31, 2020 and 2019 are referred to as the first quarter of 2020 and 2019, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

Significant Accounting Policies

The significant accounting policies used in preparation of these condensed consolidated financial statements for the three months ended March 31, 2020 are consistent with those discussed in Note 2 to the consolidated financial statements in the Company’s 2020 Annual Report on Form 10-K and are updated below as necessary.

8


 

Going Concern

At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.

The Company’s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company’s cash needs, and comparing those needs to the current cash, cash equivalent and marketable securities balances. After considering the Company’s current research and development plans, commercialization activities, including the build out of our salesforce and commercial infrastructure to support the launch of TAZVERIK in the ES indication and an expansion of our infrastructure to support a potential commercial launch in FL, and the timing expectations related to the progress of its programs, and after considering its existing cash, cash equivalents and marketable securities as of March 31, 2020, the Company did not identify conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued.

 

Pending Accounting Pronouncements

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements, or ASC 808, which clarifies certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. A retrospective adoption to the date the Company adopted ASC 606 is required by recognizing a cumulative-effect adjustment to the opening balance or retained earnings of the earliest period presented. The Company is currently evaluating the impact of the adoption of this standard on its financial statements.

In December 2019, the FASB issued ASU 2019-12, Income Taxes, or ASC 740, which simplifies the accounting for income taxes. The ASU will be effective for the Company in the first quarter of fiscal 2021, with early adoption permitted. The Company has not yet assessed the impact of this standard on its financial statements.

Recently Adopted Accounting Pronouncements

Financial Instruments – Credit Losses

In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses, or ASC 326, which requires earlier recognition of credit losses on financing receivables and other financial assets in scope. The new standard is effective for annual reporting periods beginning after December 15, 2019.

Effective January 1, 2020, the Company adopted ASC 326 using the required modified retrospective approach and utilizing the effective date as its date of initial application, for which prior periods are presented in accordance with the previous guidance in ASC 326, Financial Instruments – Credit Losses, or ASC 326.

The adoption of this standard resulted in an immaterial allowance for credit losses on the Company’s condensed consolidated balance sheet. The adoption of the standard did not have a material effect on the Company’s condensed consolidated statements of operations and comprehensive loss or condensed consolidated statements of cash flows. As of March 31, 2020, the Company had no balances to record under the transition guidance within the new standard.

 

Revenue Recognition

 

The Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services. To determine revenue recognition, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For a further discussion of accounting for net product revenue see Note 3, “Revenue Recognition”.

9


 

Accounts Receivable

The Company extends credit to customers based on its evaluation of the customer’s financial condition. The Company records receivables for all billings when amounts are due under standard terms. Accounts receivable are stated at amounts due net of applicable prompt pay discounts and other contractual adjustments as well as an allowance for doubtful accounts. The Company assesses the need for an allowance for doubtful accounts by considering a number of factors, including the length of time trade accounts receivable are past due, the customer’s ability to pay its obligation and the condition of the general economy and the industry as a whole. The Company will write-off accounts receivable when the Company determines that they are uncollectible. In general, the Company has experienced no significant collection issues with its customers.

Inventories

 

The Company outsources the manufacturing of TAZVERIK for the treatment of adult and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection and uses contract manufacturers that produce the raw and intermediate materials used in the production of TAZVERIK as well as the finished product. The Company currently has one supplier qualified for each step in the manufacturing process and is in the process of qualifying additional suppliers.

Inventories are composed of raw materials, intermediate materials, which are classified as work-in-process, and finished goods, which are goods that are available for sale. The Company states inventories at the lower of cost or net realizable value with the cost based on the first-in, first-out method. If the Company identifies excess, obsolete or unsalable items, it writes down its inventory to its net realizable value in the period in which the impairment is identified. These adjustments are recorded based upon various factors related to the product, including the level of product manufactured by the Company, the level of product in the distribution channel, current and projected demand, the expected shelf-life of the product and firm inventory purchase commitments. Shipping and handling costs incurred for inventory purchases are included in inventory costs and costs incurred for product shipments are recorded as incurred in cost of product revenue.

Prior to receiving approval from the FDA on January 23, 2020 to sell TAZVERIK, the Company expensed all costs incurred related to the manufacture of TAZVERIK as research and development expense because of the inherent risks associated with the development of a product candidate, the uncertainty about the regulatory approval process and the lack of history for the Company of regulatory approval of drug candidates.

Intangible Assets, Net

Intangible assets consist of capitalized milestone payments made to third parties under an in-license of patent rights upon receiving regulatory approval of TAZVERIK. The finite lived intangible assets are being amortized on a straight-line basis over the expected time period the Company will benefit from the in-licensed rights, which is generally the patent life. Intangible assets are recorded at cost at the time of their acquisition and are stated in the Company’s condensed consolidated balance sheets net of accumulated amortization and impairments, if applicable. The amortization expense is recognized as cost of product revenue in the Company’s condensed consolidated statement of operations. During the first quarter of 2020 the Company paid a $25.0 million milestone payment under its agreement with Eisai upon regulatory approval of tazemetostat for epithelioid sarcoma.  This regulatory milestone has been capitalized as an intangible asset.

 

The following table presents intangible assets as of March 31, 2020 (in thousands):

 

 

 

March 31, 2020

 

 

Estimated useful

life (years)

 

In-licensed rights

 

$

25,000

 

 

 

12.2

 

Less: accumulated amortization

 

 

(298

)

 

 

 

 

Total intangible asset, net

 

$

24,702

 

 

 

 

 

 

The Company recorded approximately $0.3 million in amortization expense related to intangible assets, using the straight-line methodology which is considered the best estimate of economic benefit, during the three months ended March 31, 2020. Estimated future amortization expense for intangible assets for the year ended December 31, 2020 is $1.3 million and approximately $1.8 million per year thereafter.

 

The Company assesses its intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or nonclinical data regarding one of the Company’s drug candidates or a potentially competitive drug candidate,

10


 

changes in the clinical development program for a drug candidate, or new information regarding potential sales for the drug. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value.

3. Product Revenue, Net

The Company sells TAZVERIK in the United States principally to a limited number of specialty pharmacies, which dispense the product directly to patients, and specialty distributors, which in turn sell the product to hospital pharmacies and community practice pharmacies (collectively, healthcare providers) for the treatment of patients. The specialty pharmacies and specialty distributors are referred to as the Company’s customers.

Revenue is recognized by the Company when the customer obtains control of the product, which occurs at a point in time, typically when the product is received by the Company’s customers. The Company provides a right of return to its customers for unopened product for a limited time before and after its expiration date, which lapses upon shipment to a patient. Healthcare providers to whom specialty distributors sell TAZVERIK hold limited inventory that is designated for patients, and the Company is able to monitor inventory levels in the distribution channel, thereby limiting the risk of return.

 

Reserves for Variable Consideration

 

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates, co-pay assistance and other allowances that are offered within contracts between the Company and its customers, health care providers, payors and other indirect customers relating to the Company’s product sales. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other than a customer). Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which the Company is entitled based on the terms of the contract. The amount of variable consideration that is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

 

Trade Discounts and Allowances: The Company generally provides customers with discounts that include incentive fees that are explicitly stated in customer contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain customers. To the extent the services received are distinct from the Company’s sale of products to the customer, these payments are classified in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss.

 

Product Returns: Consistent with industry practice, the Company generally offers customers a limited right of return based on the product’s expiration date for product that has been purchased from the Company, which lapses upon shipment to a patient. The Company estimates the amount of product sales that may be returned by customers and records this estimate as a reduction of revenue in the period in which the related product revenue is recognized. The Company currently estimates product return liabilities using available industry data and the Company’s own historical sales information, including our visibility into the inventory remaining in the distribution channel.

 

Provider Chargebacks and Discounts: Chargebacks for fees and discounts to healthcare providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivable. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting

11


 

period end that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed but for which the Company has not yet issued a credit.

 

Government Rebates: The Company is subject to discount obligations under state Medicaid programs and Medicare. The Company estimates its Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period in which the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the Company’s consolidated balance sheet. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of i